Risk factor
Considerable default risk
Profitability factor
Greatly overvalued vs peers
About
tella, Inc. researches and develops regenerative and cell medicines. The company offers techniques and operational knowhow associated with dendritic cell vaccine therapy to affiliated medical institutions for the treatment of cancer. It is also involved in the provision of consultation services on the establishment and maintenance of cell processing centers, and on introduction of management systems for cell cultivation; and lease of standard operating procedure and regular checks on manufacturing operation management and training of cell cultivation technicians. In addition, the company provides consultation services on training of expertise regarding treatment practice; and support services for the assessment of therapies, documentation required for treatment practice, and cognition and information providing activities for physicians and patients. tella, Inc. was founded in 2004 and is based in Tokyo, Japan.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued